Contribution of PNPLA3 gene polymorphisms to hepatocellular carcinoma susceptibility in the Chinese Han population

Gong, Dongwei; Li, Shizong; Yu, Zhishui; Wang, Kaiqiong; Qiao, Xuguang; Wu, Chang-Xiong

doi:10.1186/s12920-022-01394-7

Cited by 3 publications

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hepatocellular carcinoma (HCC) is associated with numerous risk factors, including alcohol addiction, age, gender, smoking, exposure to dietary toxins such as aflatoxins and aristolochic acid. However, the most significant causes of HCC are infected with the Hepatitis B virus (HBV) and Hepatitis C virus (HCV) [ 38 , 39 ].…”

Section: Discussionmentioning

confidence: 99%

Milk thistle nano-micelle formulation promotes cell cycle arrest and apoptosis in hepatocellular carcinoma cells through modulating miR-155-3p /SOCS2 /PHLDA1 signaling axis

Rahnama,

Tehrankhah,

Mohajerani

et al. 2023

BMC Complement Med Ther

View full text Add to dashboard Cite

Background Hepatocellular Carcinoma (HCC) is a prevalent form of liver cancer that causes significant mortality in numerous individuals worldwide. This study compared the effects of milk thistle (MT) and nano-milk thistle (N-MT) on the expression of the genes that participate in apoptosis and cell cycle pathways in Huh-7 and HepG2 cells. Methods IC50 values of MT and N-MT were determined using the MTT assay. Huh-7 and HepG2 cell lines (containing mutant and wild-type TP53 gene, respectively) were incubated with MT and N-MT for 24h and 48h and the impact of MT and N-MT on the proliferation of these cell lines was evaluated through a comparative analysis. Cell cycle and apoptosis were assessed by flow cytometry after 24h and 48h treatment in the cell lines mentioned. Real-time PCR was used to analyze miR-155-3p, PHLDA1, SOCS2, TP53, P21, BAX, and BCL-2 expression in the cell lines that were being treated. Results N-MT reduces cancer cell growth in a time and concentration-dependent manner, which is more toxic compared to MT. Huh-7 was observed to have IC50 values of 2.35 and 1.7 μg/ml at 24h and 48h, and HepG2 was observed to have IC50 values of 3.4 and 2.6 μg/ml at 24 and 48h, respectively. N-MT arrested Huh-7 and HepG2 cells in the Sub-G1 phase and induced apoptosis. N-MT led to a marked reduction in the expression of miR-155-3p and BCL-2 after 24h and 48h treatments. Conversely, PHLDA1, SOCS2, BAX, and P21 were upregulated in the treated cells compared to untreated cells, which suggests that milk thistle has the potential to regulate these genes. N-MT reduced the expression of TP53 in Huh-7 cells after mentioned time points, while there was a significant increase in the expression of the TP53 gene in HepG2 cells. No gene expression changes were observed in MT-treated cells after 24h and 48h. Conclusion N-MT can regulate cancer cell death by arresting cell cycle and inducing apoptosis. This occurs through the alteration of apoptotic genes expression. A reduction in the expression of miR-155-3p and increase in the expression of SOCS2 and PHLDA1 after N-MT treatment showed the correlation between miR-155-3p and PHLDA1/SOCS2 found in bioinformatics analysis. While N-MT increased TP53 expression in HepG2, reduced it in Huh-7. The findings indicate that N-MT can function intelligently in cancer cells and can be a helpful complement to cancer treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Milk thistle nano-micelle formulation promotes cell cycle arrest and apoptosis in hepatocellular carcinoma cells through modulating miR-155-3p /SOCS2 /PHLDA1 signaling axis

Rahnama,

Tehrankhah,

Mohajerani

et al. 2023

BMC Complement Med Ther

View full text Add to dashboard Cite

show abstract

“…More recently, Wang et al highlighted five SNPs involving genes PNPLA3 and SAMM50, all with OR > 1.5, believed to be highly associated with the development of HCC after controlling for both BMI and hepatitis virus infection [32]. Both genes are located on chromosome 22q13.31 and PNPLA3 has previously been strongly associated with the development of HCC and NAFLD [33][34][35][36].…”

Section: Risk Stratificationmentioning

confidence: 99%

Emerging and Clinically Accepted Biomarkers for Hepatocellular Carcinoma

Fares,

Wehrle,

Hong

et al. 2024

Cancers

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death and the sixth most diagnosed malignancy worldwide. Serum alpha-fetoprotein (AFP) is the traditional, ubiquitous biomarker for HCC. However, there has been an increasing call for the use of multiple biomarkers to optimize care for these patients. AFP, AFP-L3, and prothrombin induced by vitamin K absence II (DCP) have described clinical utility for HCC, but unfortunately, they also have well established and significant limitations. Circulating tumor DNA (ctDNA), genomic glycosylation, and even totally non-invasive salivary metabolomics and/or micro-RNAS demonstrate great promise for early detection and long-term surveillance, but still require large-scale prospective validation to definitively validate their clinical validity. This review aims to provide an update on clinically available and emerging biomarkers for HCC, focusing on their respective clinical strengths and weaknesses.

show abstract

Correlation between PNPLA3 rs3747207 Polymorphism and Non-Alcoholic Fatty Liver Disease

孙¹

2023

ACM

View full text Add to dashboard Cite

Contribution of PNPLA3 gene polymorphisms to hepatocellular carcinoma susceptibility in the Chinese Han population

Cited by 3 publications

References 32 publications

Milk thistle nano-micelle formulation promotes cell cycle arrest and apoptosis in hepatocellular carcinoma cells through modulating miR-155-3p /SOCS2 /PHLDA1 signaling axis

Milk thistle nano-micelle formulation promotes cell cycle arrest and apoptosis in hepatocellular carcinoma cells through modulating miR-155-3p /SOCS2 /PHLDA1 signaling axis

Emerging and Clinically Accepted Biomarkers for Hepatocellular Carcinoma

Correlation between PNPLA3 rs3747207 Polymorphism and Non-Alcoholic Fatty Liver Disease

Contact Info

Product

Resources

About